- KBI Biopharma has entered into a collaboration with Infinimmune to advance the manufacturing of IFX-101, the biotech’s lead human monoclonal antibody candidate for atopic dermatitis.
- The partnership will utilise KBI’s SUREmAb™ platform at its Cell Line Development Centre of Excellence in Geneva, Switzerland.
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and global CDMO, has partnered with Infinimmune to progress IFX-101, the biotechnology company’s first therapeutic candidate. The antibody is designed to provide improved efficacy and extended dosing intervals for patients with atopic dermatitis.
IFX-101 is derived from Infinimmune’s approach of sourcing antibodies directly from the human immune system. Its GLIMPSE™ platform, a protein language model trained on native human antibody sequences, is used alongside its Anthrobody® technology to design antibodies with enhanced biologic properties.
The programme is being advanced at KBI’s Cell Line Development Centre of Excellence in Geneva, using the company’s monoclonal antibody development and contract manufacturing platform, SUREmAb™, which is powered by Selexis. Katie Edgar, Chief Business Officer of KBI Biopharma, said: “Our strategic partnership will be highly synergistic in biologics development, by combining Infinimmune’s cutting-edge antibody discovery with KBI’s deep expertise in development and manufacturing capabilities.”
Wyatt McDonnell, Ph.D., CEO and Co-Founder of Infinimmune, added that the collaboration would accelerate the company’s path to clinical trials and support its aim of delivering more effective treatments with greater convenience for patients.
